FIG. 1A



Continuous Schedule (CS)
Compound A35 qd
1 wk on / 3wks off after 3-10 cycles qd
At toxicity: Re-challenge at resolution with IS
At POD: Change to CS

FIG. 1B



Intermittent Schedule (IS)
Compound A35 qd For 2 cycles
Cycle ≥3 1 wk on / 3wks off
At toxicity: Re-challenge at resolution with IS
At POD: Change to CS

FIG. 2



Best Change from Baseline of Measurable Lesions (N = 49*)
CS Cmpd.A35 Alone
CS Cmpd.A35 + Rituximab
IS Cmpd.A35 Alone
IS Cmpd.A35 + Rituximab
100%
75%
50%
25%
0%
-25%
-50%
-75%
-100%
*1 patient had clinical PD in Cycle 2
Overall CR Rate: 20%

FIG. 3




FIG. 4



Idelalisib
4h
24h
80
60
40
20
0
B-cell Tumor
Plasma
Compound A35
4h
24h
100,000
75,000
50,000
25,000
0
B-cell Tumor
Plasma

FIG. 5



Open Label
All subjects
Cmpd. A35 60mg qd (CS) X 2 cycles
N=150
Group A
Cmpd. A35 60mg qd (CS)
until toxicity or POD (N=75)
Group B
Cmpd. A35 60mg qd, 1 wk on / 3wks off (IS)
until toxicity or POD (N=75)
At toxicity: Change to IS
At POD: Discontinue
At toxicity: Re-challenge at resolution with IS
At POD: Change to CS
Screening (28 Days)
Randomized (within 2 Days of Day 1)
Disease assessments on Day 1 of cycles 3, 5 and 7
Disease assessments approximately every 12 wks. on Day 1 of cycle 10,13,16,19,22 and 25

FIG. 6A




1000
100
10
1
Conc (ng/ml)
0
7
14
21
Day

FIG. 6B


Modeling of QW Dosing
Concentration, nM
1000
100
10
1
20 mg QW
IC90
IC50
0
24
48
72
96
120
144
168
Time, h